Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4970366 | 0.93 | USP2 (0.49) | XBP1BRD4USP2HTTPDE4B | |
| SCHEMBL14489753 | 0.93 | XBP1 (0.43) | XBP1BRD4PDE4B | |
| SCHEMBL14489760 | 0.92 | ERBB2 (0.46) | XBP1BRD4USP2HTTPDE4B | |
| SCHEMBL21612785 | 0.91 | XBP1 (0.40) | XBP1 | |
| SCHEMBL21612803 | 0.91 | PDE4D (0.47) | XBP1BRD4PDE4BMAPTGPR119 | |
| SCHEMBL14489755 | 0.87 | EGFR (0.39) | XBP1GPR119 | |
| SCHEMBL14489747 | 0.84 | EGFR (0.48) | PDE4B | |
| SCHEMBL14489761 | 0.83 | ERBB2 (0.47) | — | |
| SCHEMBL14489789 | 0.83 | EGFR (0.43) | HTTPDE4BALDH1A1 | |
| SCHEMBL14489763 | 0.83 | GPR119 (0.46) | BRD4MAPTGPR119ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | HIMMELSBACH FRANK | 2007-06-14 | — | — | US | disclosed |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | HIMMELSBACH FRANK | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | BPHL, CYP11B2, CYP11B1 | XBP1 4713/4885BRD4 1478/4885USP2 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.